News | December 25, 2023
Lyndra Therapeutics raises US$101 million in Series E funding
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
The companies will work with investigators to share the results with the scientific community
The campaign for the digital film is being amplified across various digital media platforms such as YouTube, Facebook, Instagram, Twitter, and LinkedIn
Subscribe To Our Newsletter & Stay Updated
